中国社区医师Issue(5)：48-49,2.DOI:10.3969/j.issn.1007-614x.2016.5.27
西妥昔单抗联合FOLFIRI治疗转移性结肠癌的临床观察
Clinical observation of cetuximab combined with FOLFIRI in the treatment of metastatic colorectal cancer
刘瑾1
作者信息
- 1. 655000云南省曲靖市第一人民医院肿瘤科
- 折叠
摘要
Abstract
Objective:To investigate the curative effect and adverse reactions of cetuximab combined with FOLFIRI in the treatment of metastatic colorectal cancer.Methods:10 cases of patients with metastatic colorectal cancer were treated with cetuximab combined with FOLFIRI.Results:The effective rate was 20%,and the disease control rate was 80%.The median time of tumor progression was 9.7 weeks and the median survival time (MST) was 42 weeks.1 cases had severe allergic reaction,10 cases of patients had acne-like rash.Conclusion:Cetuximab combined with FOLFIRI in the treatment of metastatic colorectal cancer had higher response rate.关键词
转移性结肠癌/西妥昔单抗/化学治疗Key words
Metastatic colorectal cancer/Cetuximab/Chemotherapy引用本文复制引用
刘瑾..西妥昔单抗联合FOLFIRI治疗转移性结肠癌的临床观察[J].中国社区医师,2016,(5):48-49,2.
